PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 142 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.34 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,232,051 | +22.0% | 133,816 | +102.0% | 0.01% | 0.0% |
| Q2 2023 | $1,830,129 | -40.0% | 66,261 | -50.1% | 0.01% | -87.0% |
| Q1 2023 | $3,051,410 | -46.7% | 132,670 | -74.7% | 0.05% | -55.8% |
| Q4 2022 | $5,720,135 | +559.0% | 524,302 | +409.3% | 0.10% | +511.8% |
| Q3 2022 | $868,000 | -57.4% | 102,943 | -60.0% | 0.02% | -69.6% |
| Q2 2022 | $2,036,000 | +157.4% | 257,357 | +670.8% | 0.06% | +166.7% |
| Q1 2022 | $791,000 | -76.4% | 33,390 | -65.9% | 0.02% | -79.8% |
| Q4 2021 | $3,352,000 | +1772.6% | 97,998 | +868.7% | 0.10% | +1980.0% |
| Q3 2021 | $179,000 | – | 10,116 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $56,331,209 | 18.32% |
| Kynam Capital Management, LP | 1,375,000 | $31,625,000 | 4.08% |
| BVF INC/IL | 3,775,900 | $86,845,700 | 3.18% |
| Cormorant Asset Management, LP | 1,700,000 | $39,100 | 2.58% |
| RTW INVESTMENTS, LP | 4,600,799 | $105,818,377 | 2.20% |
| Ghost Tree Capital, LLC | 225,000 | $5,175,000 | 1.53% |
| 683 Capital Management, LLC | 791,000 | $18,193,000 | 1.36% |
| Ikarian Capital, LLC | 211,400 | $4,862,200 | 1.10% |
| Ikarian Capital, LLC | 211,400 | $4,862,200 | 1.10% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 105,486 | $2,426,178 | 1.00% |